Relieves heartburn associated with erosive esophagitis. Sold as Voquezna. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Vonoprazan Fumarate (sold as Voquezna), first approved Nov 1, 2023, with 0 new uses approved and 1 published complete response letter.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Voquezna | Part D | $120M | +285% | 36,442 |
| Nov 1, 2023 | VoqueznaNDA 215151 · New indication | Phathom | 2 | Marketed |
| Jul 17, 2024 | VoqueznaNDA 218710 · New indication | Phathom Pharmaceuticals Inc | 0 | Marketed |
| Letter | Product | Now |
|---|---|---|
| Feb 7, 2023 | Voquezna (vonoprazan) | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA